Loading...
XNAS
ZNTL
Market cap345mUSD
Jul 09, Last price  
4.70USD
1D
-3.29%
1Q
-28.90%
IPO
-80.73%
Name

Zentalis Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ZNTL chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.86%
Rev. gr., 5y
%
Revenues
0k
-100.00%
14,0000000067,425,0000
Net income
-137m
L-17.35%
-21,067,000-45,663,000-117,841,000-158,725,000-236,806,000-292,191,000-165,839,000-137,060,000
CFO
-125m
L-26.70%
-24,251,000-39,143,000-86,825,000-154,093,000-163,751,000-207,822,000-170,860,000-125,247,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
URL
https://www.zentalis.com/
IPO date
Apr 03, 2020
Employees
156
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT